Christoph Sotriffer

List of Publications by Year in Descending Order

43 papers	353 citations	12 h-index	17 g-index
50 ext. papers	512 ext. citations	3.8 avg, IF	3.66 L-index

#	Paper	IF	Citations
43	Photoswitchable Pseudoirreversible Butyrylcholinesterase Inhibitors Allow Optical Control of Inhibition and Enable Restoration of Cognition in an Alzheimer's Disease Mouse Model upon Irradiation.. *Journal of the American Chemical Society*, **2022**,	16.4	4
42	Molecular Insights into Site-Specific Interferon-α2a Bioconjugates Originated from PEG, LPG, and PEtOx. *Biomacromolecules*, **2021**, 22, 4521-4534	6.9	4
41	Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects and Neuroprotective Effects in a Pharmacological Alzheimer's Disease Mouse Model. *Journal of Medicinal Chemistry*, **2021**, 64, 3794-3812	8.3	15
40	Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders. *Journal of Medicinal Chemistry*, **2021**, 64, 10682-10710	8.3	9
39	C-2-Linked Dimeric Strychnine Analogues as Bivalent Ligands Targeting Glycine Receptors. *Journal of Natural Products*, **2021**, 84, 382-394	4.9	0
38	A Long Residence Time Enoyl-Reductase Inhibitor Explores an Extended Binding Region with Isoenzyme-Dependent Tautomer Adaptation and Differential Substrate-Binding Loop Closure. *ACS Infectious Diseases*, **2021**, 7, 746-758	5.5	0
37	Melatonin receptor ligands: A pharmaco-chemical perspective. *Journal of Pineal Research*, **2020**, 69, e12672	16.4	18
36	PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase. *Nature Chemical Biology*, **2020**, 16, 1179-1188	11.7	31
35	Tacrine-xanomeline and tacrine-iperoxo hybrid ligands: Synthesis and biological evaluation at acetylcholinesterase and M muscarinic acetylcholine receptors. *Bioorganic Chemistry*, **2020**, 96, 103633	5.1	6
34	Controlling Supramolecular Structures of Drugs by Light. *Molecular Pharmaceutics*, **2020**, 17, 4704-4708	5.6	2
33	How To Design Selective Ligands for Highly Conserved Binding Sites: A Case Study Using -Myristoyltransferases as a Model System. *Journal of Medicinal Chemistry*, **2020**, 63, 2095-2113	8.3	1
32	Elucidating the Molecular Basis for Inhibitory Neurotransmission Regulation by Artemisinins. *Neuron*, **2019**, 101, 673-689.e11	13.9	16
31	11-Aminostrychnine and -(Strychnine-11-yl)propionamide: Synthesis, Configuration, and Pharmacological Evaluation at Glycine Receptors. *Journal of Natural Products*, **2019**, 82, 2332-2336	4.9	2
30	Autoinhibition Mechanism of the Ubiquitin-Conjugating Enzyme UBE2S by Autoubiquitination. *Structure*, **2019**, 27, 1195-1210.e7	5.2	9
29	Highly Selective Butyrylcholinesterase Inhibitors with Tunable Duration of Action by Chemical Modification of Transferable Carbamate Units Exhibit Pronounced Neuroprotective Effect in an Alzheimer's Disease Mouse Model. *Journal of Medicinal Chemistry*, **2019**, 62, 9116-9140	8.3	31
28	Activity-based classification circumvents affinity prediction problems for pyrrolidine carboxamide inhibitors of InhA. *Journal of Molecular Graphics and Modelling*, **2018**, 80, 76-84	2.8	
27	Structural Basis of Substrate Recognition and Covalent Inhibition of Cdu1 from Chlamydia trachomatis. *ChemMedChem*, **2018**, 13, 2014-2023	3.7	5

26	Docking of Covalent Ligands: Challenges and Approaches. *Molecular Informatics*, **2018**, 37, e1800062	3.8	19
25	Novel bipharmacophoric inhibitors of the cholinesterases with affinity to the muscarinic receptors M and M. *MedChemComm*, **2017**, 8, 1346-1359	5	8
24	Dissecting the Specificity of Adenosyl Sulfamate Inhibitors Targeting the Ubiquitin-Activating Enzyme. *Structure*, **2017**, 25, 1120-1129.e3	5.2	27
23	Extending the Scope of GTFR Glucosylation Reactions with Tosylated Substrates for Rare Sugars Synthesis. *ChemBioChem*, **2017**, 18, 2012-2015	3.8	1
22	Aminobenzimidazoles and Structural Isomers as Templates for Dual-Acting Butyrylcholinesterase Inhibitors and hCB2 R Ligands To Combat Neurodegenerative Disorders. *ChemMedChem*, **2016**, 11, 1270-83	3.7	20
21	Oxime Ethers of (E)-11-Isonitrosostrychnine as Highly Potent Glycine Receptor Antagonists. *Journal of Natural Products*, **2016**, 79, 2997-3005	4.9	5
20	Scoring Functions for Protein□igand Interactions **2012**, 237-263		9
19	Ligand-Based Virtual Screening. *Methods and Principles in Medicinal Chemistry*, **2011**, 61-85	0.4	15
18	Virtual Screening of Chemical Space: From Generic Compound Collections to Tailored Screening Libraries. *Methods and Principles in Medicinal Chemistry*, **2011**, 1-33	0.4	1
17	The Basis for Target-Based Virtual Screening: Protein Structures. *Methods and Principles in Medicinal Chemistry*, **2011**, 87-114	0.4	6
16	Pharmacophore Models for Virtual Screening. *Methods and Principles in Medicinal Chemistry*, **2011**, 115-152	0.4	5
15	Applied Virtual Screening: Strategies, Recommendations, and Caveats. *Methods and Principles in Medicinal Chemistry*, **2011**, 291-318	0.4	10
14	Scenarios and Case Studies: Examples for Ligand-Based Virtual Screening. *Methods and Principles in Medicinal Chemistry*, **2011**, 359-379	0.4	1
13	Virtual Screening on Homology Models. *Methods and Principles in Medicinal Chemistry*, **2011**, 381-410	0.4	3
12	Protein Flexibility in Structure-Based Virtual Screening: From Models to Algorithms. *Methods and Principles in Medicinal Chemistry*, **2011**, 223-244	0.4	4
11	Fragment-Based Approaches in Virtual Screening. *Methods and Principles in Medicinal Chemistry*, **2011**, 467-489	0.4	2
10	The Challenge of Affinity Prediction: Scoring Functions for Structure-Based Virtual Screening. *Methods and Principles in Medicinal Chemistry*, **2011**, 177-221	0.4	14
9	Consideration of Water and Solvation Effects in Virtual Screening. *Methods and Principles in Medicinal Chemistry*, **2011**, 263-289	0.4	8

8	Handling Protein Flexibility in Docking and High-Throughput Docking: From Algorithms to Applications. *Methods and Principles in Medicinal Chemistry*, **2011**, 245-262	0.4	4
7	Applications and Success Stories in Virtual Screening. *Methods and Principles in Medicinal Chemistry*, **2011**, 319-358	0.4	17
6	Docking Methods for Virtual Screening: Principles and Recent Advances. *Methods and Principles in Medicinal Chemistry*, **2011**, 153-176	0.4	14
5	Preparing and Filtering Compound Databases for Virtual and Experimental Screening. *Methods and Principles in Medicinal Chemistry*, **2011**, 35-59	0.4	6
4	Target-Based Virtual Screening on Small-Molecule Protein Binding Sites. *Methods and Principles in Medicinal Chemistry*, **2011**, 411-434	0.4	
3	Target-Based Virtual Screening to Address Protein–Protein Interfaces. *Methods and Principles in Medicinal Chemistry*, **2011**, 435-465	0.4	
2	Appendix A: Software Overview. *Methods and Principles in Medicinal Chemistry*, **2011**, 491-499	0.4	
1	Appendix B: Virtual Screening Application Studies. *Methods and Principles in Medicinal Chemistry*, **2011**, 501-509	0.4	